D
uring the last few years, the expression patterns and roles of response gene to complement 32 (RGC-32) in various cells and diseases have been hot topics. 1 RGC-32 can act as a cell cycle regulator and is involved not only in cell proliferation 2 but also in cell differentiation. RGC-32 was found to be essential for TGF-β-induced vascular smooth muscle cell differentiation from neural crest cells. 3 The RGC-32 expression levels were significantly higher in unstimulated peripheral CD14 + cells from hyper-immunoglobulin E syndrome patients compared with those from healthy controls. 4 Moreover, RGC-32 was identified to be co-localized with CD68 + cells in multiple sclerosis plaques. 5 The above studies and importance of monocytes/macrophages in immune regulation drove us to explore the expression and function of RGC-32 in monocytes/macrophages.
We explored the expression and function of RGC-32 in the differentiation of macrophages from monocytes. Although RGC-32 was barely detectable in THP-1 cells, its expression was significantly elevated after stimulation by phorbol 12-myristate 13-acetate. 6 Notably, we found that RGC-32 was not related to the differentiation of macrophages from monocytes, as confirmed by another group. 7 We further analyzed the association of RGC-32 with polarized macrophages. RGC-32 expression in macrophages was induced by IL-4 or macrophage colonystimulating factor, but was reduced by LPS. Meanwhile, RGC-32 expression was positively related to production of the anti-inflammatory cytokine TGF-β, but negatively related to production of the proinflammatory cytokine IL-6, indicating that RGC-32 may be a hallmark of polarized M2 macrophages, 6 which is also consistent with a report showing that RGC-32 − / − murine macrophages had the M1 macrophage phenotype. 7 The two studies implied that targeting RGC-32 may increase the antitumor effects of macrophages. Both up-and down-regulated expression of RGC-32 have been observed in various human cancers. 1 However, expression of RGC-32 in both cancer cells and tumor-associated macrophages should be further clarified, and the potential therapeutic effect of targeting RGC-32 might be elicited in the future. 8 In addition, RGC-32 − / − mice resulted in fetal growth restriction by interrupting placental angiogenesis, which implies that RGC-32 is essential for normal pregnancy. 9 Macrophages account for 20-25% of all decidual leukocytes at the maternal-fetal interface, while a successful pregnancy requires appropriately and timely regulated macrophage polarization in all stages of pregnancy. 10 Whether RGC-32 modulates macrophage polarization during pregnancy and thereby contributes to maternal-fetal homeostasis remains to be investigated.
In addition to its roles in regulating cell proliferation and differentiation or polarization, RGC-32 is also involved in cell migration and invasion. It was reported that pre-eclampsia (PE) is associated with insufficient invasion of extravillous trophoblasts and subsequent incomplete spiral artery remodeling. We explored the roles of RGC-32 in PE. Our results showed that RGC-32 expression was significantly lower in pre-eclamptic placentas compared with normal controls and that RGC-32 may be correlated with the pathophysiology of PE by directly regulating the invasion/migration ability of trophoblasts. 11 Recently, RGC-32 was reported to be a key mediator of lipid and glucose metabolism. 12-14 RGC-32 can activate the liver X receptor to induce expression of SREBP-1c and its target genes, facilitating de novo lipogenesis and leading to the development of hepatic steatosis. 12 Expression of RGC-32 can be induced by a high-fat diet (HFD) in vivo and glucose in vitro. RGC-32 in endothelial cells can upregulate expression of glucagon-like peptide 2 receptor and downregulate expression of glutaminefructose-6-phosphate aminotransferase (isomerizing) 1, as well as and solute carrier family 2 (facilitated glucose transporter), member 12, contributing to the maintenance of the homeostasis of blood glucose. 13 Compared to wild-type controls, RGC-32 knockout mice fed with HFD were leaner with improved insulin resistance. 14 Gestational diabetes mellitus (GDM), one of the most common metabolic complications of pregnancy, is characterized by carbohydrate intolerance that begins or is first diagnosed during pregnancy. 15 It is important to determine the roles of RGC-32 and underling mechanisms in the pathogenesis of GDM.
In summary, RGC-32 has crucial immunological roles, and further experiments are expected to reveal the associations of RGC-32 with various human diseases in the future.
